Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OFIX's Cash to Debt is ranked higher than
97% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. OFIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OFIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.31 Max: No Debt
Current: No Debt
Equity to Asset 0.71
OFIX's Equity to Asset is ranked higher than
66% of the 292 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. OFIX: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
OFIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.67 Max: 0.85
Current: 0.71
0.36
0.85
Interest Coverage 36.22
OFIX's Interest Coverage is ranked lower than
58% of the 219 Companies
in the Global Medical Devices industry.

( Industry Median: 76.81 vs. OFIX: 36.22 )
Ranked among companies with meaningful Interest Coverage only.
OFIX' s Interest Coverage Range Over the Past 10 Years
Min: 0.68  Med: 3.2 Max: 36.22
Current: 36.22
0.68
36.22
F-Score: 7
Z-Score: 6.27
WACC vs ROIC
4.56%
-0.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.92
OFIX's Operating margin (%) is ranked higher than
51% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. OFIX: 3.92 )
Ranked among companies with meaningful Operating margin (%) only.
OFIX' s Operating margin (%) Range Over the Past 10 Years
Min: -49.44  Med: 3.34 Max: 17.01
Current: 3.92
-49.44
17.01
Net-margin (%) -0.37
OFIX's Net-margin (%) is ranked lower than
54% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. OFIX: -0.37 )
Ranked among companies with meaningful Net-margin (%) only.
OFIX' s Net-margin (%) Range Over the Past 10 Years
Min: -43.98  Med: -1.32 Max: 9.73
Current: -0.37
-43.98
9.73
ROE (%) -0.53
OFIX's ROE (%) is ranked lower than
54% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. OFIX: -0.53 )
Ranked among companies with meaningful ROE (%) only.
OFIX' s ROE (%) Range Over the Past 10 Years
Min: -71.87  Med: -1.4 Max: 16.37
Current: -0.53
-71.87
16.37
ROA (%) -0.39
OFIX's ROA (%) is ranked higher than
50% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. OFIX: -0.39 )
Ranked among companies with meaningful ROA (%) only.
OFIX' s ROA (%) Range Over the Past 10 Years
Min: -31.59  Med: -0.88 Max: 7.45
Current: -0.39
-31.59
7.45
ROC (Joel Greenblatt) (%) 11.78
OFIX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. OFIX: 11.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OFIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -121.91  Med: 9.79 Max: 27.87
Current: 11.78
-121.91
27.87
Revenue Growth (3Y)(%) -2.40
OFIX's Revenue Growth (3Y)(%) is ranked lower than
70% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. OFIX: -2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OFIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 12.1 Max: 17.7
Current: -2.4
-10.5
17.7
EBITDA Growth (3Y)(%) -31.20
OFIX's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. OFIX: -31.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OFIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.8  Med: 9.9 Max: 63.2
Current: -31.2
-49.8
63.2
» OFIX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OFIX Guru Trades in Q3 2015

Diamond Hill Capital 815,876 sh (+5.00%)
Jim Simons 133,679 sh (+3.08%)
Paul Tudor Jones Sold Out
Mario Gabelli 101,225 sh (-0.30%)
Chuck Royce 96,600 sh (-9.04%)
Arnold Schneider 66,094 sh (-18.39%)
» More
Q4 2015

OFIX Guru Trades in Q4 2015

Paul Tudor Jones 13,797 sh (New)
Jim Simons 255,359 sh (+91.02%)
Diamond Hill Capital 861,860 sh (+5.64%)
Chuck Royce 95,800 sh (-0.83%)
Mario Gabelli 98,825 sh (-2.37%)
Arnold Schneider 37,184 sh (-43.74%)
» More
Q1 2016

OFIX Guru Trades in Q1 2016

Jim Simons 456,379 sh (+78.72%)
Paul Tudor Jones 22,708 sh (+64.59%)
Diamond Hill Capital 1,014,826 sh (+17.75%)
Mario Gabelli 99,125 sh (+0.30%)
Chuck Royce 73,200 sh (-23.59%)
Arnold Schneider 21,065 sh (-43.35%)
» More
Q2 2016

OFIX Guru Trades in Q2 2016

Jim Simons 570,179 sh (+24.94%)
Diamond Hill Capital 1,068,717 sh (+5.31%)
Chuck Royce 73,200 sh (unchged)
Arnold Schneider Sold Out
Mario Gabelli 96,325 sh (-2.82%)
Paul Tudor Jones 18,595 sh (-18.11%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:CSII, NAS:KTWO, NAS:VASC, NYSE:ITGR, OTCPK:SBMAF, NYSE:CRY, NAS:MDXG, NAS:HTWR, NAS:SPNC, OTCPK:BSNRY, OTCPK:MZRTF, NAS:GNMK, NAS:CNMD, NAS:ARAY, NAS:XENT, NAS:EXAC, NYSE:IVC, NAS:INGN, NAS:CYNO, NAS:AXGN » details
Traded in other countries:OFX.Germany,
Orthofix International NV is a diversified medical device company. The Company is engaged in developing and delivering repair & regenerative solutions to the spine and orthopedic markets.

Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine

Ratios

vs
industry
vs
history
Forward P/E 23.87
OFIX's Forward P/E is ranked higher than
50% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.39 vs. OFIX: 23.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.05
OFIX's P/B is ranked lower than
52% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. OFIX: 3.05 )
Ranked among companies with meaningful P/B only.
OFIX' s P/B Range Over the Past 10 Years
Min: 0.77  Med: 2 Max: 3.32
Current: 3.05
0.77
3.32
P/S 1.99
OFIX's P/S is ranked higher than
62% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. OFIX: 1.99 )
Ranked among companies with meaningful P/S only.
OFIX' s P/S Range Over the Past 10 Years
Min: 0.31  Med: 1.56 Max: 2.39
Current: 1.99
0.31
2.39
PFCF 26.18
OFIX's PFCF is ranked higher than
54% of the 100 Companies
in the Global Medical Devices industry.

( Industry Median: 28.91 vs. OFIX: 26.18 )
Ranked among companies with meaningful PFCF only.
OFIX' s PFCF Range Over the Past 10 Years
Min: 6.45  Med: 19.02 Max: 572.14
Current: 26.18
6.45
572.14
POCF 14.59
OFIX's POCF is ranked higher than
61% of the 132 Companies
in the Global Medical Devices industry.

( Industry Median: 20.89 vs. OFIX: 14.59 )
Ranked among companies with meaningful POCF only.
OFIX' s POCF Range Over the Past 10 Years
Min: 5.7  Med: 12.01 Max: 274.6
Current: 14.59
5.7
274.6
EV-to-EBIT 46.79
OFIX's EV-to-EBIT is ranked lower than
80% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 21.78 vs. OFIX: 46.79 )
Ranked among companies with meaningful EV-to-EBIT only.
OFIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -38  Med: 17.2 Max: 272.1
Current: 46.79
-38
272.1
EV-to-EBITDA 46.79
OFIX's EV-to-EBITDA is ranked lower than
87% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 16.76 vs. OFIX: 46.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
OFIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -144.1  Med: 11.9 Max: 769.5
Current: 46.79
-144.1
769.5
Current Ratio 2.31
OFIX's Current Ratio is ranked lower than
55% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. OFIX: 2.31 )
Ranked among companies with meaningful Current Ratio only.
OFIX' s Current Ratio Range Over the Past 10 Years
Min: 1.56  Med: 3.42 Max: 5.24
Current: 2.31
1.56
5.24
Quick Ratio 1.51
OFIX's Quick Ratio is ranked lower than
62% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. OFIX: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
OFIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 2.57 Max: 3.82
Current: 1.51
1.13
3.82
Days Inventory 240.02
OFIX's Days Inventory is ranked lower than
76% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 132.94 vs. OFIX: 240.02 )
Ranked among companies with meaningful Days Inventory only.
OFIX' s Days Inventory Range Over the Past 10 Years
Min: 201.26  Med: 244.73 Max: 336.86
Current: 240.02
201.26
336.86
Days Sales Outstanding 50.42
OFIX's Days Sales Outstanding is ranked higher than
75% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. OFIX: 50.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
OFIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.42  Med: 82.39 Max: 105.88
Current: 50.42
50.42
105.88
Days Payable 55.51
OFIX's Days Payable is ranked lower than
53% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. OFIX: 55.51 )
Ranked among companies with meaningful Days Payable only.
OFIX' s Days Payable Range Over the Past 10 Years
Min: 48.79  Med: 69.53 Max: 101.56
Current: 55.51
48.79
101.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.20
OFIX's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. OFIX: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OFIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.1  Med: -1.5 Max: 1.2
Current: 1.2
-7.1
1.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.02
OFIX's Price/Net Current Asset Value is ranked lower than
67% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.14 vs. OFIX: 11.02 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OFIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.2  Med: 5.21 Max: 235
Current: 11.02
2.2
235
Price/Tangible Book 4.01
OFIX's Price/Tangible Book is ranked higher than
51% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.38 vs. OFIX: 4.01 )
Ranked among companies with meaningful Price/Tangible Book only.
OFIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.48  Med: 4.42 Max: 110.32
Current: 4.01
1.48
110.32
Price/Projected FCF 1.95
OFIX's Price/Projected FCF is ranked higher than
57% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. OFIX: 1.95 )
Ranked among companies with meaningful Price/Projected FCF only.
OFIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.3 Max: 2.51
Current: 1.95
0.55
2.51
Price/Median PS Value 1.27
OFIX's Price/Median PS Value is ranked lower than
64% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. OFIX: 1.27 )
Ranked among companies with meaningful Price/Median PS Value only.
OFIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 1.15 Max: 2.3
Current: 1.27
0.32
2.3
Earnings Yield (Greenblatt) (%) 2.10
OFIX's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. OFIX: 2.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OFIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 4.6 Max: 18.7
Current: 2.1
0.4
18.7
Forward Rate of Return (Yacktman) (%) 3.12
OFIX's Forward Rate of Return (Yacktman) (%) is ranked lower than
64% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 7.76 vs. OFIX: 3.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OFIX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -41.7  Med: 4.2 Max: 32.7
Current: 3.12
-41.7
32.7

More Statistics

Revenue (TTM) (Mil) $408.5
EPS (TTM) $ -0.09
Beta0.39
Short Percentage of Float1.76%
52-Week Range $32.25 - 48.25
Shares Outstanding (Mil)18.12

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 415 431 448 466
EPS ($) 1.41 1.83 2.00 2.15
EPS w/o NRI ($) 1.41 1.83 2.00 2.15
EPS Growth Rate
(3Y to 5Y Estimate)
17.40%
Dividends Per Share ($)
» More Articles for OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International N.V. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Orthofix International NV – Value Analysis (NASDAQ:OFIX) : September 13, 2016 Sep 13 2016
Orthofix International NV breached its 50 day moving average in a Bearish Manner : OFIX-US :... Sep 12 2016
Orthofix Announces First Patient Enrollment in Osteoarthritis of the Knee Study Sep 12 2016
Orthofix Announces First Patient Enrollment in Osteoarthritis of the Knee Study Sep 12 2016
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 09 2016
Orthofix International NV breached its 50 day moving average in a Bullish Manner : OFIX-US :... Sep 01 2016
ETF’s with exposure to Orthofix International NV : August 22, 2016 Aug 22 2016
Orthofix International NV :OFIX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
ORTHOFIX INTERNATIONAL N V Financials Aug 06 2016
Orthofix International N.V. (OFIX) Is in Oversold Territory: What's Next? Aug 05 2016
Orthofix to Present at the Canaccord Genuity 36th Annual Growth Conference Aug 04 2016
Orthofix International NV breached its 50 day moving average in a Bearish Manner : OFIX-US : August... Aug 03 2016
Edited Transcript of OFIX earnings conference call or presentation 1-Aug-16 9:00pm GMT Aug 02 2016
Orthofix International Reports Second Quarter 2016 Financial Results Aug 01 2016
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 01 2016
Orthofix reports 2Q loss Aug 01 2016
Orthofix reports 2Q loss Aug 01 2016
Orthofix International Reports Second Quarter 2016 Financial Results Aug 01 2016
Q2 2016 Orthofix International NV Earnings Release - After Market Close Aug 01 2016
Orthofix Announces Japanese Approval and Market Launch of PHOENIX Minimally Invasive Spinal Fixation... Jul 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)